NSE: AARTIPHARM | BSE: 543748

Mid-range Performer

Download real time

719.25 12.65 (1.79%)

25.93% Fall from 52W High

102.9K NSE+BSE Volume

NSE 14 May, 2026 3:31 PM (IST)

6,520.6

Market Cap

Above industry Median

Beta 1Year

High Volatility

Board Meeting

The next board meeting for Aarti Pharmalabs is on 18 May 2026 for the purpose of Audited Results & Final Dividend See details

Aarti Pharmalabs Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for AARTIPHARM, BSE:543748 Aarti Pharmalabs Ltd.

Search Inside the pdf :

Aarti Pharmalabs Ltd.

11 Feb 2026

719.25

1.79%

Aarti Pharmalabs

Buy: Aarti Pharmalabs Ltd.

Target

ICICI Direct

Q3FY26 Sequential improvement driven by CDMO despite postponement of one shipment Revenues for the quarter improved 3.3% QoQ to 432.3 crore. EBITDA for the quarter grew by 36.9% QoQ to 102.3 crore and margins to 23.7% mainly driven by 1020 bps QoQ improvement in GPM to 60.1%. PAT for the quarter stood at 48 crore. The growth was subdued in Xanthine and API/ Intermediates segments which reported almost flat numbers sequentially 208 crore and 165 crore respectively. The CDMO segment reported 30% growth QoQ to 53 crore on lower base...

Promoters pledged 11.02% of shares in last quarter. Total pledge stands at 11.03% of promoter holdings

Aarti Pharmalabs Ltd.

14 Nov 2025, 12:00AM

719.25

1.79%

Aarti Pharmalabs

Buy: Aarti Pharmalabs Ltd.

ICICI Direct

Capacity expansion across segments to steer growth beyond FY26Xanthine segment primarily witnessed the growth on account of capacity debottlenecking of ~1000 MTPA thereby taking overall capacity to 6000 MTPA from 5000 MTPA. The company remains on track to expand its capacity to 9000 MTPA by Q4FY26. Prices of xanthine remained stable, as per management. We believe APL to focus more on grabbing the larger wallet share across Pharma and beverage customers (higher margin opportunities). On the CDMO front, the management is confident of achieving its guidance of 30-40% growth on back of strong order book...

Promoters pledged 11.02% of shares in last quarter. Total pledge stands at 11.03% of promoter holdings